CA2473586A1 - Treatment of sleep disorders using sleep target modulators - Google Patents

Treatment of sleep disorders using sleep target modulators Download PDF

Info

Publication number
CA2473586A1
CA2473586A1 CA002473586A CA2473586A CA2473586A1 CA 2473586 A1 CA2473586 A1 CA 2473586A1 CA 002473586 A CA002473586 A CA 002473586A CA 2473586 A CA2473586 A CA 2473586A CA 2473586 A1 CA2473586 A1 CA 2473586A1
Authority
CA
Canada
Prior art keywords
compound
group
therapeutic compound
therapeutic
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002473586A
Other languages
English (en)
French (fr)
Inventor
David G. Hangauer
Harry Jefferson Leighton
Dale M. Edgar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hypnion Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2473586A1 publication Critical patent/CA2473586A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002473586A 2002-01-18 2003-01-21 Treatment of sleep disorders using sleep target modulators Abandoned CA2473586A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34991202P 2002-01-18 2002-01-18
US60/349,912 2002-01-18
US35732002P 2002-02-15 2002-02-15
US60/357,320 2002-02-15
PCT/US2003/001845 WO2003068148A2 (en) 2002-01-18 2003-01-21 Treatment of sleep disorders using sleep target modulators

Publications (1)

Publication Number Publication Date
CA2473586A1 true CA2473586A1 (en) 2003-08-21

Family

ID=27737408

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002473586A Abandoned CA2473586A1 (en) 2002-01-18 2003-01-21 Treatment of sleep disorders using sleep target modulators

Country Status (6)

Country Link
US (2) US20060009465A1 (enExample)
EP (1) EP1471913A2 (enExample)
JP (1) JP2005519073A (enExample)
AU (1) AU2003210598A1 (enExample)
CA (1) CA2473586A1 (enExample)
WO (1) WO2003068148A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047759A1 (es) * 2003-09-26 2006-02-22 Vertex Pharma Derivados de fenil - piperazina como moduladores de receptores muscarnicos
EP1740198A4 (en) * 2004-04-26 2009-03-04 Immuneregen Biosciences Inc ANTI-AGING EFFECT OF SUBSTANCE P
JP4613031B2 (ja) * 2004-05-06 2011-01-12 エスエス製薬株式会社 催眠剤組成物
WO2007048220A2 (en) * 2005-09-09 2007-05-03 Labopharm Inc. Trazodone composition for once a day adminisitiation
JP2009507047A (ja) * 2005-09-09 2009-02-19 ラボファーム インコーポレイテッド 持続性薬物放出組成物
WO2007098202A2 (en) 2006-02-16 2007-08-30 Imthera Medical, Inc. An rfid based apparatus, system, and method for therapeutic treatment of a patient
US20110077200A1 (en) * 2006-12-06 2011-03-31 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
AU2008311313A1 (en) 2007-10-09 2009-04-16 Imthera Medical, Inc. System and method for neural stimulation
US8428725B2 (en) 2008-10-09 2013-04-23 Imthera Medical, Inc. Method of stimulating a Hypoglossal nerve for controlling the position of a patient's tongue
ES2370147T5 (es) 2009-10-23 2019-03-06 Gruppo Cimbali Spa Máquina de café con regulación de presión de distribución y procedimiento relacionado con la misma
BR112012010986A2 (pt) 2009-11-10 2016-04-12 Imthera Medical Inc sistema para estimular um nervo hipoglosso para o controle da posição da língua de um paciente
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
KR101809305B1 (ko) 2011-02-11 2017-12-14 제트엑스 파마 엘엘씨 다중미립자 l-멘톨 제제 및 관련 방법
US20120315337A1 (en) * 2011-06-07 2012-12-13 Shah Syed Multiparticulate 5-htp compositions and related methods
US9266881B2 (en) 2011-11-14 2016-02-23 Merck Sharp & Dohme Corp. Triazolopyridinone PDE10 inhibitors
BR112015006499A2 (pt) 2013-04-23 2017-07-04 Zx Pharma Llc composição de óleo de horlelã-pimenta de liberação controlada microparticulada com revestimento entérico e métodos relacionados
BR112017020307B1 (pt) 2015-03-26 2023-11-07 Jacqueline M. Iversen Usos de uma combinação de naproxeno e fexofenadina
WO2019192903A1 (de) * 2018-04-06 2019-10-10 Basf Se Verfahren zur herstellung von aminen
JP2025539064A (ja) * 2022-11-11 2025-12-03 ギルガメッシュ・ファーマシューティカルズ・インコーポレイテッド トラゾドンを使用して5-ht2a受容体アゴニストの効果を逆転させる方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116852A (en) * 1990-12-03 1992-05-26 Bristol-Myers Squibb Co. Treatment of sleep disorders

Also Published As

Publication number Publication date
AU2003210598A2 (en) 2003-09-04
US20060009465A1 (en) 2006-01-12
EP1471913A2 (en) 2004-11-03
JP2005519073A (ja) 2005-06-30
AU2003210598A1 (en) 2003-09-04
WO2003068148A3 (en) 2004-04-01
US20030232839A1 (en) 2003-12-18
WO2003068148A2 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
US20030232839A1 (en) Treatment of sleeping disorders using CNS sleep target modulators
US7355042B2 (en) Treatment of CNS disorders using CNS target modulators
US7317026B2 (en) CNS target modulators
JP5186219B2 (ja) 置換アリールアミン化合物および5−ht6調節因子としてのその使用
JP2007534696A5 (enExample)
HUT75878A (en) N-substituted azaheterocyclic carboxylic acids and esters thereof, pharmaceutical compositions containing them, process for their preparation and their use for treatment of neurogenic inflammations
CN1028756C (zh) 新的吡啶基和嘧啶基衍生物的制备方法
US7189757B2 (en) Treatment of sleep disorders using CNS target modulators
JPS6136281A (ja) ベンゾチオフエン下痢止め薬
CN115304593A (zh) 苯并异噻唑化合物及其药物组合物和应用
CN115304590A (zh) 2h-苯并三氮唑衍生物及其制备方法及含有它们的药物组合物
JPH06511231A (ja) 2−(ピロリジニル−1−メチル)−ピペリジン誘導体およびκ受容体アゴニストとしてのその使用
CN87105791A (zh) 喹唑啉二酮和吡啶并嘧啶二酮及其制备方法
US3549656A (en) Antidepressant 1 - aminoalkyl - thiophthalanes and acid addition salts thereof
WO2007092334A1 (en) Method of treating sleep disorders
WO2007092333A1 (en) Use of olopatadine for treating sleep disorders
US5180726A (en) 4-[4- or 6-(trifluoromethyl-2-pyridinyl)]-1-piperazinylalkyl substituted lactams
KR20090057055A (ko) 옥세핀 유도체
JPWO2005113501A1 (ja) 神経因性疼痛制御剤組成物
JP2000507569A (ja) 抗精神病薬ならびに鎮痛薬を製造するための、1,1―ジアルキル―1,2,3,4―テトラヒドロイソキノリンの使用

Legal Events

Date Code Title Description
FZDE Dead